2-氯-1-(3,4-二甲氧基苯基)乙酮 | 20601-92-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-1-(3,4-二甲氧基苯基)乙酮
• 英文名称: 3,4-dimethoxyphenacyl chloride
• 英文别名: 2-Chloro-1-(3,4-dimethoxyphenyl)ethanone
• CAS: 20601-92-7
• 化学式: C₁₀H₁₁ClO₃
• 分子量: 214.649
• InChiKey: NHBJPPQEPIPTLF-UHFFFAOYSA-N

物化性质

• 熔点：
  101 °C
• 沸点：
  190 °C(Press: 12 Torr)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  2-氯-1-(3,4-二甲氧基苯基)乙酮 在 sodium azide 、 dimethyl sulfide borane 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (-)-(R)-3,4-di-O-methylnorepinephrine
  参考文献：
  名称：

  Kershaw; Wright; Sharma, Current Medicinal Chemistry, 2013, vol. 20, # 4, p. 569 - 575

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二甲氧基苯乙酮 在 N,N,N-trimethylbenzenemethanaminium dichloroiodate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以81.5 %的产率得到2-氯-1-(3,4-二甲氧基苯基)乙酮
  参考文献：
  名称：

  利用金鸡纳生物碱衍生的 NNP 配体 Ir 催化 α-卤代酮不对称氢化生产 (R)- 和 (S)- 卤代醇

  摘要：

  利用易于获取的基于金鸡纳生物碱的 NNP 配体，开发了铱催化剂对 α-卤化酮的不对称氢化。通过该协议，各种 α-氯苯乙酮、杂环噻吩基和呋喃基底物，甚至溴酮完全转化为所需的手性卤代醇。( R )- 和 ( S )- 手性卤代醇都可以通过改变手性配体 NNP 的构型来制备，分别具有高达 99.6% ee（对映体过量）和 98.8% ee。此外，有效地进行了克级实验。

  DOI：

  10.1021/acs.joc.2c02109

文献信息

• Copper(I)-Promoted Synthesis of Chloromethyl Ketones from Trichloromethyl Carbinols
  作者：Ram N. Ram、T. P. Manoj

  DOI：10.1021/jo8007644

  日期：2008.7.1

  Reaction of several trichloromethyl carbinols with 2 equiv of CuCl/bpy in refluxing DCE for 3 h afforded chloromethyl ketones in excellent yield by 1,2-H shift in the copper-chlorocarbenoid intermediate.

  几种三氯甲基甲醇与2当量的CuCl / bpy在回流DCE中反应3小时，得到的氯甲基酮的收率很高，通过铜-氯类化合物中间体的1,2-H转移。
• Asymmetric Synthesis of β-Adrenergic Blockers through Multistep One-Pot Transformations Involving In Situ Chiral Organocatalyst Formation
  作者：Shengwei Wei、Regina Messerer、Svetlana B. Tsogoeva

  DOI：10.1002/chem.201102931

  日期：2011.12.16

  Two birds one stone: A new atom‐economical one‐pot approach to enantioselective chiral drug synthesis, involving in situ multistep organocatalyst formation and the application of the reaction for multistep sequential synthesis of β‐adrenergic blockers is disclosed (see scheme).

  两只鸟一块石头：公开了一种用于对映选择性手性药物合成的新的原子经济单罐方法，该方法涉及原位多步有机催化剂的形成以及该反应在β-肾上腺素能阻滞剂多步序贯合成中的应用（参见方案）。
• Iridium-Catalyzed Asymmetric Hydrogenation of Halogenated Ketones for the Efficient Construction of Chiral Halohydrins
  作者：Congcong Yin、Weilong Wu、Yang Hu、Xuefeng Tan、Cai You、Yuanhua Liu、Ziyi Chen、Xiu-Qin Dong、Xumu Zhang

  DOI：10.1002/adsc.201800267

  日期：2018.6.5

  Iridium‐catalyzed asymmetric hydrogenation of prochiral halogenated ketones was successfully developed to prepare various chiral halohydrins with high reactivities and excellent enantioselectivities under basic reaction condition (up to >99% conversion, 99% yield, >99% ee). Moreover, gram‐scale experiment was performed well in the presence of just 0.005 mol% (S/C=20 000) Ir/f‐amphox catalyst with 99%

  成功开发了铱催化的前手性卤代酮的不对称氢化反应，以制备各种在碱性反应条件下具有高反应性和出色的对映选择性的手性卤代醇（转化率> 99％，收率99％，ee> 99％）。此外，在仅有0.005 mol％（S / C = 20 000）Ir / f-amphox催化剂存在下，克级实验性能良好，产率为99％，ee大于99％。
• Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry
  作者：Sanji Hagishita、Kaoru Seno、Susumu Kamata、Nobuhiro Haga、Yasunobu Ishihara、Michio Ishikawa、Mayumi Shimamura

  DOI：10.1016/s0968-0896(97)00083-7

  日期：1997.7

  relationship studies revealed that carbonylmethyl groups at both N-1 and N-5 positions and hydrophilic groups, such as the carboxyl group on the benzene ring attached to the ureido group at the C-3 position, brought about potent affinity and subtype selectivity for CCK-B/gastrin receptors. Several compounds showed excellent in vivo inhibition of gastric acid secretion induced by pentagastrin in anesthetized

  设计，合成了一系列具有对称平面的CCK-B /胃泌素受体拮抗剂，2,4-二氧代-1,5-苯并二氮杂卓衍生物，并评估了其拮抗活性。构效关系研究表明，在N-1和N-5位置上的羰基甲基和亲水基团（例如在C-3位置与脲基相连的苯环上的羧基）带来了强大的亲和力和亚型对CCK-B /胃泌素受体的选择性。在麻醉的大鼠中，几种化合物对五肽胃泌素诱导的胃酸分泌具有出色的体内抑制作用。
• Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
  作者：Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior

  DOI：10.2174/1573406417666210216154428

  日期：2022.2

  Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

  Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

  A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

  The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

  The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

  背景：利什曼病是全球性健康问题，在发展中国家高度流行。在该病的四种主要临床形式中，内脏利什曼病是最严重的，95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性，迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮（AGH）已被探索用于展示多样的生物活性，特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮（TSC）提供类似的生物活性多样性，包括对利什曼病和克氏锥虫的抗原虫效应。 目的：考虑到利什曼病在全球范围内的影响，本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选，以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法：首先合成了一组AGH（3-7）、TSC（9, 10）和半胱氨酮（11）。随后，设计并制备了不同的半约束类似物，包括噻唑烷（12）、二氢噻嗪（13）、咪唑烷（15）、嘧啶（16, 18）、吲哚烷（19, 20）和苯并三唑环酮（23-25）。所有中间体和目标化合物均以满意的收率获得，并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果：AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，最大效果高达55.3％，满意的SI值（范围从11到87）。另一方面，大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言，TSC类比其同功异构AGH类更有前景，而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论：三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估，这将有助于选择最佳的命中物进行体内实验。